MET and ovarian cancer: Ovarian cancer patients most commonly had alterations in TP53 (N = 32, 64.0%), PIK3CA (N = 9, 18.0%), KRAS (N = 8, 16.0%), BRAF (N = 8, 16.0%), MYC (N = 6, 12.0%), MET (N = 6, 12.0%), CDK6 (N = 6, 12.0%), CCNE1 (N = 5, 10.0%), and EGFR (N = 5, 10.0%; Fig. 2B).